When investigating a correlation between mutational burden in tumors and sensitivity to PD-1 blockade, Rizvi et al. have shown that a higher nonsynonymous mutation or candidate neoantigen burden in tumors from anti-PD-1-treated NSCLC patients was associated with improved PFS [81]. The gene discussed is PDCD1; the disease is non-small cell lung carcinoma.